Pfizer Corporation

Jeffrey L Ives

Frank C Sciavolino

David S Watt

Peptide-substituted heterocyclic compounds having the formula below, pharmaceutically acceptable salts thereof and intermediates therefor; processes for their preparation and use as immunostimulant and antiinfective agents. ##STR1## wherein R is a 5- or 6-membered N-containing heterocyclyl moiety which can have an additional hetero atom selected from N, S or O; R.sup.1 is hydrogen or (C.sub.1-4)alkyl; x is 0 or an integer from 1 to 5; and y is 0 or 1; provided that when y is 0, said N-containing heterocyclyl moiety is linked to the ##STR2## group at its N atom.

Peptide-substituted heterocyclic immunostimulants

Acyltripeptides having the formula below, pharmaceutically acceptable salts thereof and intermediates therefor; processes for their preparation and use as immunostimulant and antibacterial agents. ##STR1## wherein R.degree. is C.sub.1-6 alkyl; x is an integer and is 1 to 4.

Acyltripeptide immunostimulants

A series of phenylguanidine base compounds and their pharmaceutically acceptable acid addition salts have been found to be active as oral hypoglycemic agents. Preferred member compounds include N,N'-diphenyl-1-pyrrolidinocarboxamidine, N-phenyl-N'-methyl-N'-phenyl-1-pyrrolidinocarboxamidine and N-phenyl-N'-(p-chlorophenyl)-1-pyrrolidinocarboxamidine, and their hydrohalide acid addition salts. Synthetic routes leading to these compounds are described.

Phenylguanidine therapeutic agents

Novel guanylamidines and the pharmaceutically acceptable acid addition salts thereof having activity as hypoglycemic agents are disclosed.

Growing community of inventors

King of Prussia, PA, United States of America

Jeffrey L Ives